Active/recruiting trials studying treatment approaches for metastatic uveal melanoma as registered on ClinicalTrials.gov.

ClinicalTrials.gov identifier	Drug	Phase	Planned patients	Status	Sponsor
NCT01355120	Ipilimumab (anti-CTLA4 antibody)	II	41	Data collection ongoing	University Hospital Essen, Germany
NCT01034787	CP-675,206 (anti-CTLA4 antibody)	II	32	Data collection ongoing	Alberta Health Services, Canada
NCT01585194	Ipilimumab (anti-CTLA4 antibody)	II	141	Recruiting	MD Anderson Cancer Center, US
NCT01587352	Vorinostat (histone deacetylase inhibitor)	II	32	Recruiting	National Cancer Institute, US
NCT01413191	Cixutumumab (anti-IGF-1R antibody)	II	32	Data collection ongoing	National Cancer Institute, US
NCT01200342	Genasense/oblimersen (Bcl-2 antisense oligonucleotide) plus carboplatin/paclitaxel	II	30	Data collection ongoing	MD Anderson Cancer Center, US
NCT00506142	Marqibo (liposomal vincristine)	II	50	Recruiting	Talon Therapeutics, US
NCT00738361	Abraxane (nab-paclitaxel)	II	25	Completed, results pending	National Comprehensive Cancer Network, Ohio, US
NCT01252251	Everolimus (mTOR inhibitor) and pasireotide (somatostatin receptor analog)	II	25	Recruiting	Memorial Sloan-Kettering Cancer Center, US
NCT01200238	Ganetespib (HSP90 inhibitor)	II	30	Recruiting	Dana-Farber Cancer Institute, US
NCT01143402	Selumetinib (MEK inhibitor) versus temozolomide	II	159	Recruiting	National Cancer Institute, US
NCT01430416	AEB071 (protein kinase C inhibitor)	I	65	Recruiting	Novartis Pharmaceuticals, US
NCT01377025	Sorafenib versus placebo	II	200	Recruiting	University Hospital, Essen, Germany
NCT01801358	AEB071 (protein kinase C inhibitor) plus MEK162	I/II	90	Not yet recruiting	Novartis Pharmaceuticals, US
NCT01835145	Cabozantinib versus temozolomide or dacarbazine	II	69	Not yet recruiting	National Cancer Institute, US